



Enzon Pharmaceuticals Inc.  
Investor Relations Department  
20 Kingsbridge Road  
Attn: Accounts Payable  
Piscataway, NJ 08854  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#) 

#### OT: ENZN <sup>1</sup>

Last Trade: 0.29

Trade Time: 3:54 PM ET  
Dec 15, 2017

Change: -0.01   
(-3.317%)

Day Range 0.29 - 0.31

52-Week Range 0.03 - 0.40

Volume 242,377

Market Cap. (\$M) 12.824


Shares Out (M) 44.220

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron®, Sylatron®, Macugen® and CIMZIA®. ... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

May 1, 2014  
[Enzon Adopts Stockholder Rights Plan in an Effort to Protect Net Operating Loss Carryforwards](#)

Apr 23, 2013  
[Enzon Concludes Review of Possible Asset Sales, Sale of the Company; Announces \\$1.60 Special Dividend and Periodic Royalty Dividends](#)

Mar 18, 2013  
[Enzon Reports Fourth Quarter and Full Year 2012 Results](#)

Dec 17, 2012  
[Enzon to Review Asset Sales, Sale of the Company](#)

Nov 29, 2012  
[Enzon Announces Special Dividend](#)

### Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

### Financials [\[ View all \]](#)

Mar 24, 2017  
[Annual Report \(10-K\)](#)

May 12, 2017  
[Definitive Proxy Statement](#)

Nov 9, 2017  
[Quarterly Report \(10-Q\)](#)

Aug 10, 2017  
[Quarterly Report \(10-Q\)](#)

May 11, 2017  
[Quarterly Report \(10-Q\)](#)